CSI Market
Sign In | Register

Adverum Biotechnologies Inc (ADVM) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access ADVM Annual Cash Flow →
Observing cash flow movements over recent quarters helps explain how Adverum Biotechnologies Inc adapts cash usage as operating conditions change.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2025)
9 Months 		(Jun 30 2025) (Mar 31 2025) (Dec 31 2024) (Sep 30 2024)
Operating Activities
Income-143.86
Depreciation & amortization1.68
Amortization of Other Assets0.00
Accretion Expense0.00
Asset Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.01
Share-based Compensation7.55
Income (Loss) from Equity Method Investments0.00
Financial Instruments and Foreign Currency Transaction0.00
Research And Development Expense Excluding Acquired In Process Cost-
Embedded Derivative Gain Loss On Embedded Derivative Net-
Increase Decrease In Deposit And Other Noncurrent Assets-0.68
Amortization Of Premium And Accrued Interest On Marketable Securities-
Operating Lease Right Of Use Asset Amortization-
Goodwill And Intangible Asset Impairment-
Increase Decrease Operating Lease Right Of Use Asset-
Increase Decrease In Deposit And Other Noncurrent Assets And Deferred Rent Receivable-
Increase Decrease In Operating Lease Right Of Use Assets-
Operating Lease Right Of Use Asset Amortization Expense0.17
Increase Decrease In Operating Lease Liability0.67
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable10.84
Increase (Decrease) in Accrued Liabilities10.82
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets2.70
Other Working Capital0.00
Other Noncash Income (Expense)0.01
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.44
Discontinued operations0.00
Net Cash flow from Operating Activities-109.65
Investing Activities
Capital Expenditures-0.48
Sale of Capital Items0.00
Proceeds from Maturities, Prepayments and Calls of Available-for-sale Securities67.50
Payments to Acquire Available-for-sale Securities, Debt-1.98
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Cash Acquired from Acquisition0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities65.04
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock10.02
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net-62.63
Debt Conversion Converted Instrument Amount-
Issuance Of Warrants On Convertible Preferred Stock-
Deferred Offering Costs Accrued Expenses-
Warrants Issued In Connection With License Agreement-
Fixed Assets In Accounts Payable-
Payments Of Convertible Preferred Stock Issuance Costs-
Proceeds From Employee Stock Purchase Plan-
Convertible Preferred Stock Issuance Cost-
Proceeds From Offerings Of Common Stock Net Of Issuance Costs-
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents62.63
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities10.02
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-110.14
Total Cash Flow-34.59
4 historic quarters locked

Sign in to unlock the full Adverum Biotechnologies Inc cash flow history.

Sign In Create Free Account

About Adverum Biotechnologies Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-Q filings and normalized by CSIMarket.

Source & verification

  • Form: 10-Q (Period: 20250930)
  • Filed with the SEC: November 12, 2025
  • Source: advm-20250930.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001628280-25-051593

Figures are derived from filed reports and may be restated. Historical data is subject to revision.